Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemiaAlisa B. Lee‐Sherick, Douglas K. Graham|Oncogene|2013Cited by 105
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A. Minson, Douglas K. Graham|JCI Insight|2016Cited by 78
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemiaLuis Brandão, Douglas K. Graham|Blood Cancer Journal|2013Cited by 57
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemiaAlisa B. Lee‐Sherick, Douglas K. Graham|Oncotarget|2015Cited by 44
Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the NucleusJustine Migdall-Wilson, Douglas K. Graham|PLoS ONE|2012Cited by 37